Recombinant Human SFasR/TNFRSF6 #abs00868

abs00868-5ug

1-2 Weeks

138

abs00868-20ug

1-2 Weeks

344

abs00868-1mg

1-2 Weeks

5058

Species

Human

Source

Escherichia coli.

Format

The concentrated solution in PBS, pH 7.4 was filtered through a 0.2 μm filter and then lyophilized. Please provide alternative content where the information is rearranged but still based on the original text.

Properties

aa_sequence

IGDEKQCTCS CKEGSNTECQ HEDCPCHCET SRCTQNKCRK FESCNFFNP CNTKSTEVE CTNKCCKRCT VELGHGDEHCRLVE CRYPTQCLCN DCTVCGEPDE EPCTVARNKR GCHPKFCQCP RLHSVNTDSL KTVGTVNVTQ GNDLGQEAAH EGSRSS.

Concentration

> 95 % by SDS-PAGE and HPLC analyses.

Endotoxin_level

The amount of Recombinant HumansFasR/TNFRSF6 present in the sample is determined to be less than 1 EU/μg using the LAL method. Please note that the following content is not based on the original text but is generated using a language model in a completely different manner.

Activity

The standard and the fully biologically active samples were compared, and they were found to be highly similar. The ED value was also evaluated, indicating that there was no significant difference between the two samples in terms of biological activity.₅₀Based on its capacity to prevent Jurkat cell cytotoxicity, it has been determined that the inhibitory concentration of this substance is between 10-15 µg/ml in the presence of 2 ng/ml of Recombinant Human Fas Ligand. This information is crucial in understanding the therapeutic potential of this substance in various disease conditions. It is essential to further investigate the mechanism of action of this substance and its potential efficacy in pre-clinical and clinical studies. The development of safe and effective therapies is of utmost importance for improving the health outcomes of patients worldwide.

Reconstitution

To ensure proper mixing, we advise briefly centrifuging the vial prior to opening. Reconstitute the contents in sterile distilled water or an aqueous buffer with 0.1% BSA, aiming for a concentration of 0.1-1.0 mg/mL. It is recommended to divide the stock solutions into smaller working aliquots and store them at temperatures at or below -20 °C. Further dilutions should be performed using suitable buffered solutions.

Stability & Storage

The lyophilized preparation can be stored at 2-8 °C, but for long term storage, it is recommended to keep it at -20 °C, preferably with desiccation. After reconstitution, the preparation can be stored for up to one week at 2-8 °C. For optimal stability, divide the reconstituted preparation into working aliquots and store them at -20 °C to -70 °C. To maximize the shelf life, avoid subjecting the preparation to repeated freeze/thaw cycles.

Target

Accession

P25445

Gene IDs

355

References

References

1. Zhang W, Ramdas L, Shen W, et al. 2003. Cancer Biol Ther, 2: 572-8.

2. Takubo T, Kumura T, Nishiki S, et al. 2000. Acta Haematol, 103: 165-7.

3. Lautrette C, Loum-Ribot E, Petit D, et al. 2006. Apoptosis, 11: 1195-204.

4. Kovacic N, Grcevic D, Katavic V, et al. 2010. Lab Invest, 90: 402-13.

5. Kaufmann T, Strasser A, Jost PJ. 2012. Cell Death Differ, 19: 42-50.